| Route | Medication | Major brand names | Form | Dosage |
|---|---|---|---|---|
| Oral | Testosterone undecanoate | Andriol, Jatenzo | Capsule | 40–80 mg 1x/1–2 days |
| Methyltestosterone | Metandren, Estratest | Tablet | 0.5–10 mg/day | |
| Fluoxymesterone | Halotestin | Tablet | 1–2.5 mg 1x/1–2 days | |
| Normethandronea | Ginecoside | Tablet | 5 mg/day | |
| Tibolone | Livial | Tablet | 1.25–2.5 mg/day | |
| Prasterone ( DHEA)b | – | Tablet | 10–100 mg/day | |
| Sublingual | Methyltestosterone | Metandren | Tablet | 0.25 mg/day |
| Transdermal | Testosterone | Intrinsa | Patch | 150–300 μg/day |
| AndroGel | Gel, cream | 1–10 mg/day | ||
| Vaginal | Prasterone ( DHEA) | Intrarosa | Insert | 6.5 mg/day |
| Injection | Testosterone propionatea | Testoviron | Oil solution | 25 mg 1x/1–2 weeks |
| Testosterone enanthate | Delatestryl, Primodian Depot | Oil solution | 25–100 mg 1x/4–6 weeks | |
| Testosterone cypionate | Depo-Testosterone, Depo-Testadiol | Oil solution | 25–100 mg 1x/4–6 weeks | |
| Testosterone isobutyratea | Femandren M, Folivirin | Aqueous suspension | 25–50 mg 1x/4–6 weeks | |
| Mixed testosterone esters | Climacterona | Oil solution | 150 mg 1x/4–8 weeks | |
| Omnadren, Sustanon | Oil solution | 50–100 mg 1x/4–6 weeks | ||
| Nandrolone decanoate | Deca-Durabolin | Oil solution | 25–50 mg 1x/6–12 weeks | |
| Prasterone enanthatea | Gynodian Depot | Oil solution | 200 mg 1x/4–6 weeks | |
| Implant | Testosterone | Testopel | Pellet | 50–100 mg 1x/3–6 months |
| Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). [1] [2] Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: General: [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Specific: [17] [18] [19] [20] [21] [22] [23] [24] | ||||
Template documentationSee also
- Template:Androgen/anabolic steroid dosages for breast cancer
- Template:Androgen replacement therapy formulations and dosages used in men
- Template:Medications and dosages used in hormone therapy for transgender men
- Template:Clinical dosage ranges of oral and injectable androgens and anabolic steroids
References
- ^ Mauvais-Jarvis P, Kuttenn F, Mowszowicz I (6 December 2012). Hirsutism. Springer Science & Business Media. pp. 74–. ISBN 978-3-642-81571-3.
- ^ Legato (29 October 2009). Principles of Gender-Specific Medicine. Academic Press. pp. 748–. ISBN 978-0-08-092150-1.
- ^ Lobo RA (June 2001). "Androgens in postmenopausal women: production, possible role, and replacement options". Obstetrical & Gynecological Survey. 56 (6): 361–376. doi: 10.1097/00006254-200106000-00022. PMID 11466487. S2CID 9872335.
- ^ Morley JE, Perry HM (May 2003). "Androgens and women at the menopause and beyond". The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 58 (5): M409–M416. doi: 10.1093/gerona/58.5.M409. PMID 12730248.
- ^ Lobo RA, Kelsey J, Marcus R (22 May 2000). Menopause: Biology and Pathobiology. Academic Press. pp. 454–. ISBN 978-0-08-053620-0.
- ^ Bagatell C, Bremner WJ (27 May 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 374–. ISBN 978-1-59259-388-0.
- ^ Lorrain J (1994). Comprehensive Management of Menopause. Springer Science & Business Media. pp. 301–. ISBN 978-0-387-97972-4.
- ^ Khorram O (December 2001). "Potential therapeutic effects of prescribed and over-the-counter androgens in women". Clinical Obstetrics and Gynecology. 44 (4): 880–892. doi: 10.1097/00003081-200112000-00025. PMID 11600868. S2CID 40818075.
- ^ Wells BJ, DiPiro JT, Schwinghammer TL, DiPiro CV (22 August 2014). Pharmacotherapy Handbook, 9/E. McGraw-Hill Education. p. 288. ISBN 978-0-07-182129-2.
- ^ Seifern DB (27 July 1999). Menopause: Endocrinology and Management. Springer Science & Business Media. pp. 359–. ISBN 978-1-59259-246-3.
- ^ Hohl A (30 March 2017). Testosterone: From Basic to Clinical Aspects. Springer. pp. 341–343. ISBN 978-3-319-46086-4.
- ^ Nusbaum M, Rosenfeld JL (2 December 2004). Sexual Health Across the Lifecycle: A Practical Guide for Clinicians. Cambridge University Press. pp. 77–. ISBN 978-0-521-53421-5.
- ^ Davis SR (1999). "The therapeutic use of androgens in women". The Journal of Steroid Biochemistry and Molecular Biology. 69 (1–6): 177–184. doi: 10.1016/S0960-0760(99)00054-0. PMID 10418991. S2CID 23520067.
- ^ Maia H, Casoy J, Valente J (January 2009). "Testosterone replacement therapy in the climacteric: benefits beyond sexuality". Gynecological Endocrinology. 25 (1): 12–20. doi: 10.1080/09513590802360744. PMID 19165658. S2CID 40325624.
- ^ Greenblatt RB (June 1987). "Is there a place for androgens in gynecological disorders?". Gynecological Endocrinology. 1 (2): 209–219. doi: 10.3109/09513598709030684. PMID 3332535.
- ^ Shabsigh R, Davis AR, Anastasiadis AG, Makhsida N, Yan G (2005). "Female Sexual Dysfunction". Oral Pharmacotherapy for Male Sexual Dysfunction. pp. 423–443. doi: 10.1385/1-59259-871-4:423. ISBN 978-1-58829-451-7.
-
^ Josef M (14 May 2010).
Farmakoterapie vnitřních nemocí: 4., zcela přepracované a doplněné vydání. Grada Publishing a.s. pp. 380–.
ISBN
978-80-247-9524-9.
In addition, testosterone isobutyrate in FOLIVIRIN, Biotika, an injection containing 25 mg testosterone isobutyrate and 2.5 mg estradiol benzoate is available. It is applied every 4-6 weeks depending on the effect.
-
^
Ciba Symposium: 1953/57:Index. Ciba. 1953. p. 197.
Femandren M. C'est le nom des nouvelles ampoules cristallines destinées au traitement associé œs- trogène-androgène. Elles renferment, sous forme de microcristaux, 2,5 mg de mono- benzoate d'œstradiol et 50 mg d'isobutyra- te de testostérone ; elles sont indiquées pour traiter les cas où il convient d'administrer simultanément de l'hormone femelle et de l'hormone mâle et où il importe aussi d'obtenir un effet prolongé, par exemple lors de symptômes d'insuffisance à la ménopause ou après castration. L'effet d'une injection se prolonge pendant 3-6 semaines.
-
^ Borgeltn LM (2010).
Women's Health Across the Lifespan: A Pharmacotherapeutic Approach. ASHP. pp. 558–.
ISBN
978-1-58528-194-7.
Despite the lack of clinical trials and quality-control standards, custom-compounded testosterone creams, ointments, and gel forms are popular formulations for improving women's sexual desire.68-70 For women, an appropriate dosage of compounded 1% testosterone gel, cream, or ointment is 0.5 g/day, which should deliver 5 mg of testosterone daily, one tenth the generally prescribed dosage for men.39 The product can be applied directly to any skin surface (but commonly the clitoris, labia, thigh, arm, or abdomen) several times weekly.
-
^ Culligan PJ, Goldberg RP (6 March 2007).
Urogynecology in Primary Care. Springer Science & Business Media. pp. 116–.
ISBN
978-1-84628-167-9.
Topical vaginal testosterone is often used in premenopausal women as a first step in the treatment of sexual dysfunction and vaginal lichen planus. Topical testosteorne preparations can be compounded in 1% to 2% formulations and should be applied up to 3 times per week.
-
^ Papadakis MA, McPhee SJ, Rabow MW (11 September 2017).
Current Medical Diagnosis and Treatment 2018, 57th Edition. McGraw-Hill Education. p. 1217–1218.
ISBN
978-1-259-86149-9.
Testosterone can also be compounded as a cream containing 1 mg/mL, with 1 mL applied to the abdomen daily. Vaginal testosterone is an option for postmenopausal women who cannot use systemic or vaginal estrogen due to breast cancer. Testosterone 150–300 mcg/day vaginally appears to reduce vaginal dryness and dyspareunia without increasing systemic estrogen levels.
-
^ Pizzorno JE (2013).
Textbook of Natural Medicine. Elsevier Health Sciences. p. 1602.
ISBN
978-1-4377-2333-5.
At present, bioidentical testosterone can be obtained only from a compounding pharmacy, where 4 to 6 mg of bioidentical testosterone is generally formulated alone or together with the biestrogen or triestrogen formulation. Testosterone cream applied to the genital region can be used as an alternative delivery method. Common prescriptions are anywhere from 1 to 10 mg/g of cream.
- ^ "Intrarosa Information Sheet" (PDF). FDA.gov. Retrieved January 4, 2019.
- ^ Brotherton J (1976). Sex Hormone Pharmacology. Academic Press. pp. 18–19, 336. ISBN 978-0-12-137250-7.
| Route | Medication | Major brand names | Form | Dosage |
|---|---|---|---|---|
| Oral | Testosterone undecanoate | Andriol, Jatenzo | Capsule | 40–80 mg 1x/1–2 days |
| Methyltestosterone | Metandren, Estratest | Tablet | 0.5–10 mg/day | |
| Fluoxymesterone | Halotestin | Tablet | 1–2.5 mg 1x/1–2 days | |
| Normethandronea | Ginecoside | Tablet | 5 mg/day | |
| Tibolone | Livial | Tablet | 1.25–2.5 mg/day | |
| Prasterone ( DHEA)b | – | Tablet | 10–100 mg/day | |
| Sublingual | Methyltestosterone | Metandren | Tablet | 0.25 mg/day |
| Transdermal | Testosterone | Intrinsa | Patch | 150–300 μg/day |
| AndroGel | Gel, cream | 1–10 mg/day | ||
| Vaginal | Prasterone ( DHEA) | Intrarosa | Insert | 6.5 mg/day |
| Injection | Testosterone propionatea | Testoviron | Oil solution | 25 mg 1x/1–2 weeks |
| Testosterone enanthate | Delatestryl, Primodian Depot | Oil solution | 25–100 mg 1x/4–6 weeks | |
| Testosterone cypionate | Depo-Testosterone, Depo-Testadiol | Oil solution | 25–100 mg 1x/4–6 weeks | |
| Testosterone isobutyratea | Femandren M, Folivirin | Aqueous suspension | 25–50 mg 1x/4–6 weeks | |
| Mixed testosterone esters | Climacterona | Oil solution | 150 mg 1x/4–8 weeks | |
| Omnadren, Sustanon | Oil solution | 50–100 mg 1x/4–6 weeks | ||
| Nandrolone decanoate | Deca-Durabolin | Oil solution | 25–50 mg 1x/6–12 weeks | |
| Prasterone enanthatea | Gynodian Depot | Oil solution | 200 mg 1x/4–6 weeks | |
| Implant | Testosterone | Testopel | Pellet | 50–100 mg 1x/3–6 months |
| Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per 4 weeks). [1] [2] Footnotes: a = Mostly discontinued or unavailable. b = Over-the-counter. Sources: General: [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Specific: [17] [18] [19] [20] [21] [22] [23] [24] | ||||
Template documentationSee also
- Template:Androgen/anabolic steroid dosages for breast cancer
- Template:Androgen replacement therapy formulations and dosages used in men
- Template:Medications and dosages used in hormone therapy for transgender men
- Template:Clinical dosage ranges of oral and injectable androgens and anabolic steroids
References
- ^ Mauvais-Jarvis P, Kuttenn F, Mowszowicz I (6 December 2012). Hirsutism. Springer Science & Business Media. pp. 74–. ISBN 978-3-642-81571-3.
- ^ Legato (29 October 2009). Principles of Gender-Specific Medicine. Academic Press. pp. 748–. ISBN 978-0-08-092150-1.
- ^ Lobo RA (June 2001). "Androgens in postmenopausal women: production, possible role, and replacement options". Obstetrical & Gynecological Survey. 56 (6): 361–376. doi: 10.1097/00006254-200106000-00022. PMID 11466487. S2CID 9872335.
- ^ Morley JE, Perry HM (May 2003). "Androgens and women at the menopause and beyond". The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 58 (5): M409–M416. doi: 10.1093/gerona/58.5.M409. PMID 12730248.
- ^ Lobo RA, Kelsey J, Marcus R (22 May 2000). Menopause: Biology and Pathobiology. Academic Press. pp. 454–. ISBN 978-0-08-053620-0.
- ^ Bagatell C, Bremner WJ (27 May 2003). Androgens in Health and Disease. Springer Science & Business Media. pp. 374–. ISBN 978-1-59259-388-0.
- ^ Lorrain J (1994). Comprehensive Management of Menopause. Springer Science & Business Media. pp. 301–. ISBN 978-0-387-97972-4.
- ^ Khorram O (December 2001). "Potential therapeutic effects of prescribed and over-the-counter androgens in women". Clinical Obstetrics and Gynecology. 44 (4): 880–892. doi: 10.1097/00003081-200112000-00025. PMID 11600868. S2CID 40818075.
- ^ Wells BJ, DiPiro JT, Schwinghammer TL, DiPiro CV (22 August 2014). Pharmacotherapy Handbook, 9/E. McGraw-Hill Education. p. 288. ISBN 978-0-07-182129-2.
- ^ Seifern DB (27 July 1999). Menopause: Endocrinology and Management. Springer Science & Business Media. pp. 359–. ISBN 978-1-59259-246-3.
- ^ Hohl A (30 March 2017). Testosterone: From Basic to Clinical Aspects. Springer. pp. 341–343. ISBN 978-3-319-46086-4.
- ^ Nusbaum M, Rosenfeld JL (2 December 2004). Sexual Health Across the Lifecycle: A Practical Guide for Clinicians. Cambridge University Press. pp. 77–. ISBN 978-0-521-53421-5.
- ^ Davis SR (1999). "The therapeutic use of androgens in women". The Journal of Steroid Biochemistry and Molecular Biology. 69 (1–6): 177–184. doi: 10.1016/S0960-0760(99)00054-0. PMID 10418991. S2CID 23520067.
- ^ Maia H, Casoy J, Valente J (January 2009). "Testosterone replacement therapy in the climacteric: benefits beyond sexuality". Gynecological Endocrinology. 25 (1): 12–20. doi: 10.1080/09513590802360744. PMID 19165658. S2CID 40325624.
- ^ Greenblatt RB (June 1987). "Is there a place for androgens in gynecological disorders?". Gynecological Endocrinology. 1 (2): 209–219. doi: 10.3109/09513598709030684. PMID 3332535.
- ^ Shabsigh R, Davis AR, Anastasiadis AG, Makhsida N, Yan G (2005). "Female Sexual Dysfunction". Oral Pharmacotherapy for Male Sexual Dysfunction. pp. 423–443. doi: 10.1385/1-59259-871-4:423. ISBN 978-1-58829-451-7.
-
^ Josef M (14 May 2010).
Farmakoterapie vnitřních nemocí: 4., zcela přepracované a doplněné vydání. Grada Publishing a.s. pp. 380–.
ISBN
978-80-247-9524-9.
In addition, testosterone isobutyrate in FOLIVIRIN, Biotika, an injection containing 25 mg testosterone isobutyrate and 2.5 mg estradiol benzoate is available. It is applied every 4-6 weeks depending on the effect.
-
^
Ciba Symposium: 1953/57:Index. Ciba. 1953. p. 197.
Femandren M. C'est le nom des nouvelles ampoules cristallines destinées au traitement associé œs- trogène-androgène. Elles renferment, sous forme de microcristaux, 2,5 mg de mono- benzoate d'œstradiol et 50 mg d'isobutyra- te de testostérone ; elles sont indiquées pour traiter les cas où il convient d'administrer simultanément de l'hormone femelle et de l'hormone mâle et où il importe aussi d'obtenir un effet prolongé, par exemple lors de symptômes d'insuffisance à la ménopause ou après castration. L'effet d'une injection se prolonge pendant 3-6 semaines.
-
^ Borgeltn LM (2010).
Women's Health Across the Lifespan: A Pharmacotherapeutic Approach. ASHP. pp. 558–.
ISBN
978-1-58528-194-7.
Despite the lack of clinical trials and quality-control standards, custom-compounded testosterone creams, ointments, and gel forms are popular formulations for improving women's sexual desire.68-70 For women, an appropriate dosage of compounded 1% testosterone gel, cream, or ointment is 0.5 g/day, which should deliver 5 mg of testosterone daily, one tenth the generally prescribed dosage for men.39 The product can be applied directly to any skin surface (but commonly the clitoris, labia, thigh, arm, or abdomen) several times weekly.
-
^ Culligan PJ, Goldberg RP (6 March 2007).
Urogynecology in Primary Care. Springer Science & Business Media. pp. 116–.
ISBN
978-1-84628-167-9.
Topical vaginal testosterone is often used in premenopausal women as a first step in the treatment of sexual dysfunction and vaginal lichen planus. Topical testosteorne preparations can be compounded in 1% to 2% formulations and should be applied up to 3 times per week.
-
^ Papadakis MA, McPhee SJ, Rabow MW (11 September 2017).
Current Medical Diagnosis and Treatment 2018, 57th Edition. McGraw-Hill Education. p. 1217–1218.
ISBN
978-1-259-86149-9.
Testosterone can also be compounded as a cream containing 1 mg/mL, with 1 mL applied to the abdomen daily. Vaginal testosterone is an option for postmenopausal women who cannot use systemic or vaginal estrogen due to breast cancer. Testosterone 150–300 mcg/day vaginally appears to reduce vaginal dryness and dyspareunia without increasing systemic estrogen levels.
-
^ Pizzorno JE (2013).
Textbook of Natural Medicine. Elsevier Health Sciences. p. 1602.
ISBN
978-1-4377-2333-5.
At present, bioidentical testosterone can be obtained only from a compounding pharmacy, where 4 to 6 mg of bioidentical testosterone is generally formulated alone or together with the biestrogen or triestrogen formulation. Testosterone cream applied to the genital region can be used as an alternative delivery method. Common prescriptions are anywhere from 1 to 10 mg/g of cream.
- ^ "Intrarosa Information Sheet" (PDF). FDA.gov. Retrieved January 4, 2019.
- ^ Brotherton J (1976). Sex Hormone Pharmacology. Academic Press. pp. 18–19, 336. ISBN 978-0-12-137250-7.